Daruvir Tablets

DARUVIR co-administered with ritonavir (darunavir/rtv) and with other antiretroviral agents, are indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.
This indication is based on analyses of plasma HIV RNA levels and CD4+ cell counts from controlled Phase 3 trials of 48 weeks duration in antiretroviral treatment-experienced patients and controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.
In treatment-experienced adult patients, the following points should be considered when initiating therapy with DARUVIR :
Treatment history and, when available, genotypic or phenotypic testing should guide the use of DARUVIR.
The use of other active agents with DARUVIR is associated with a greater likelihood of treatment response.
DARUVIR tablets are contraindicated with drugs like Alfuzosin, Dihydroergotamine, ergonovine, ergotamine, methylergonovine, Pimozide, Orally administered Midazolam, Lovastatin, Simvastatin, Rifampin, Silden-afil for treatment of pulmonary arterial hypertension.